Anish Suri Ph.D.
Cambridge, Massachusetts, United States
4K followers
500+ connections
Activity
-
We are pleased to welcome industry veteran Lucinda Warren as chief business officer (CBO). Ms. Warren holds over 30 years of global industry…
We are pleased to welcome industry veteran Lucinda Warren as chief business officer (CBO). Ms. Warren holds over 30 years of global industry…
Liked by Anish Suri Ph.D.
-
Next week I get the chance to join fellow panelists Natalia Ulyanova, William Ho, José M. Mejía Oneto, Tim Sullivan and moderator Alex Philippidis at…
Next week I get the chance to join fellow panelists Natalia Ulyanova, William Ho, José M. Mejía Oneto, Tim Sullivan and moderator Alex Philippidis at…
Liked by Anish Suri Ph.D.
-
We look forward to the 15th Annual World Bispecific Summit, where our Director of Translational Pharmacology, Natasha Girgis, will present on…
We look forward to the 15th Annual World Bispecific Summit, where our Director of Translational Pharmacology, Natasha Girgis, will present on…
Liked by Anish Suri Ph.D.
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
Volunteer Experience
Patents
-
Antibody Polypeptides that Antagonize CD40L
Filed US WO2013056068 A1
Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents…
Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
Other inventors -
-
Antibodies Polypeptides that Antagonize CD40
Filed US WO2012145673 A1
Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents…
Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
Other inventors -
More activity by Anish
-
Nobody fakes cancer to get free chemo. This is important. Please share.
Nobody fakes cancer to get free chemo. This is important. Please share.
Liked by Anish Suri Ph.D.
-
I’m so grateful to be part of such an amazing inaugural TEDxSanDiego Women experience! An extraordinary roster of speakers and a brilliant team of…
I’m so grateful to be part of such an amazing inaugural TEDxSanDiego Women experience! An extraordinary roster of speakers and a brilliant team of…
Liked by Anish Suri Ph.D.
-
Our very own Dr. Elise Alspach, Congratulations, exciting work!
Our very own Dr. Elise Alspach, Congratulations, exciting work!
Liked by Anish Suri Ph.D.
-
NEW PODCAST - Is This the Future of CAR-T Technology? In today's podcast episode, I discuss the revolutionary concept of 'Universal CAR receptors' -…
NEW PODCAST - Is This the Future of CAR-T Technology? In today's podcast episode, I discuss the revolutionary concept of 'Universal CAR receptors' -…
Liked by Anish Suri Ph.D.
-
So, there's seems to be a problem in immuno-oncology. The field is getting crowded and it’s starting to get really loud in here. With all this…
So, there's seems to be a problem in immuno-oncology. The field is getting crowded and it’s starting to get really loud in here. With all this…
Liked by Anish Suri Ph.D.
-
I can’t believe my TEDxSanDiego Talk, “Focus on the Mirror, Not the Glass Ceiling” is next week! I hope you’ll walk away from my talk with a sense…
I can’t believe my TEDxSanDiego Talk, “Focus on the Mirror, Not the Glass Ceiling” is next week! I hope you’ll walk away from my talk with a sense…
Liked by Anish Suri Ph.D.
-
NK cells are excellent for "off-the-shelf" cell therapies. Here's one reason why. --- There are several problems with autologous T cell-based…
NK cells are excellent for "off-the-shelf" cell therapies. Here's one reason why. --- There are several problems with autologous T cell-based…
Liked by Anish Suri Ph.D.
-
Very happy to join the Neomorph board and support a fantastic team driving towards innovative medicines.
Very happy to join the Neomorph board and support a fantastic team driving towards innovative medicines.
Liked by Anish Suri Ph.D.
-
Empress CEO and cofounder @Jason Park gives a fantastic overview of how the company is harnessing machine learning, synthetic biology and recombinant…
Empress CEO and cofounder @Jason Park gives a fantastic overview of how the company is harnessing machine learning, synthetic biology and recombinant…
Liked by Anish Suri Ph.D.
-
Has anybody else noticed this? Cell-specific targeting of cytokines is gaining some serious momentum, with prominent companies in the space -…
Has anybody else noticed this? Cell-specific targeting of cytokines is gaining some serious momentum, with prominent companies in the space -…
Liked by Anish Suri Ph.D.
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More